pharma · HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER · Advanced HER2-Expressing Solid Tumors. · BOLT
Bolt Biotherapeutics
Bolt Biotherapeutics is a pharma organization headquartered in Redwood City, USA. It trades on NYSE under ticker BOLT. Primary therapeutic focus areas include HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC
Redwood City, USA HQ
2015 Founded
51 Employees
Public company Type
BOLT · NYSE Ticker
Company details
- Status
- Public
- HQ
- Redwood City, USA
- Founded
- 2015
- Employees
- 51
- Programs
- 6
- Drugs
- 4
- Patents
- 7
BDC-1001
Phase 2 · small molecule · Metastatic Breast Cancer
BDC-1001 for Metastatic Breast Cancer is a Phase 2 program (small_molecule) at Bolt Biotherapeutics with 1 ClinicalTrials.gov record(s).
Internal code BBI-20231001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Bolt Biotherapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Metastatic Breast Cancer
- Status
- terminated
- Trials
- 1